For research use only. Not for therapeutic Use.
CT1812 (Sigma-2 receptor antagonist 1) is an orally active and brain penetrant sigma-2 receptor antagonist with a Ki of 8.5 nM. CT1812 can be used for the research of Alzheimer’s disease[1].
CT1812 (0.0001-10 μM, 30 min) displaces and prevents Aβ oligomer binding in neurons and glia[1].
CT1812 (4.8 μM, 48 h) increases synaptic number and protein expression in neurons[1].
CT1812 (0.3-3 mg/kg, i.v., once time) selectively reduces Aβ oligomer extracellular concentrations in transgenic hAPP/PS1 mice[1].
CT1812 (10 mg/kg, p.o., daily, 9-10 weeks) improves cognitive performance in transgenic Thy1 huAPPSwe/Lnd+ male mice[1].
| Catalog Number | I019408 |
| CAS Number | 1802632-22-9 |
| Synonyms | 4-[3-methyl-3-(5-methylsulfonyl-1,3-dihydroisoindol-2-yl)butyl]-2-[(2-methylpropan-2-yl)oxy]phenol |
| Molecular Formula | C24H33NO4S |
| Purity | ≥95% |
| InChI | InChI=1S/C24H33NO4S/c1-23(2,3)29-22-13-17(7-10-21(22)26)11-12-24(4,5)25-15-18-8-9-20(30(6,27)28)14-19(18)16-25/h7-10,13-14,26H,11-12,15-16H2,1-6H3 |
| InChIKey | ISQAPFMBJFZOLG-UHFFFAOYSA-N |
| SMILES | CC(C)(C)OC1=C(C=CC(=C1)CCC(C)(C)N2CC3=C(C2)C=C(C=C3)S(=O)(=O)C)O |
| Reference | [1]. Izzo NJ, et al. Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer’s disease modification. Alzheimers Dement. 2021 Aug;17(8):1365-1382. |
